Pretreatment P53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus calmette-guerin (BCG)

By Saint F.   Le Frere Belda M.A.   Quitela R.   Gil Diez De Medina S.   Hoznek A.   Patard J.J.   Bellot J.   Popov Z.   Zafrani E.S.   Abbou C.C.   Chopin D.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 86-86

Elsevier

Access to resources Recommend Favorite

Do Prognostic Parameters of Remission versus Relapse after Bacillus Calmette-Guerin (BCG) Immunotherapy Exist? - Analysis of a Quarter Century of Literature

By Saint F.   Salomon L.   Quintela R.   Cicco A.   Hoznek A.   Abbou C.C.   Chopin D.K.  

European Urology, Vol. 43, Iss. 4, 2003-04 ,pp. : 351-361

Elsevier

Access to resources Recommend Favorite

Dermatofibrosarcoma protuberans arising in a bacillus Calmette-Guerin vaccination scar

By Lloyd M.  

European Journal of Plastic Surgery, Vol. 32, Iss. 1, 2009-02 ,pp. : 37-38

Springer Publishing Company

Access to resources Recommend Favorite

Penile edema and meatal ulceration after intravesical instillation with bacillus calmette-Guerin

By Baniel J.   Lev Z.   Engelstein D.   Servadio C.  

Urology, Vol. 47, Iss. 6, 1996-06 ,pp. : 932-934

Elsevier

Access to resources Recommend Favorite

Prospective evaluation of candidate urine and cell markers in patients with interstitial cystitis enrolled in a randomized clinical trial of Bacillus Calmette Guerin (BCG)

By Keay Susan  

World Journal of Urology, Vol. 25, Iss. 5, 2007-10 ,pp. : 499-504

Springer Publishing Company

Access to resources Recommend Favorite